Connecticut Mesothelioma Doctors, Cancer Centers and Treatment

If you live in the state of Connecticut and have been diagnosed with mesothelioma, you have access to a number of treatment options. Conventional mesothelioma treatments available in Connecticut include surgery, chemotherapy and radiation. Beyond these conventional treatments, clinical trials may currently be recruiting pleural and peritoneal mesothelioma patients in Connecticut.

We have listed top mesothelioma doctors that practice in Connecticut as well as the top cancer care centers in the state. Additionally for caregivers, we have located a number of local cancer treatment support services. Read more about health care options available to you in Connecticut here.

Connecticut Mesothelioma Cancer Centers

For your convenience, we have compiled a list of mesothelioma cancer centers that are located in Connecticut. Please click on a cancer center link to obtain more information about the clinical programs offered and how to contact the cancer center.

Doctors who Treat Mesothelioma in Connecticut

For your convenience, we have compiled a list of mesothelioma doctors that are located in Connecticut. Please click on a doctor link to obtain more information about their background, areas of expertise, professional affiliations, and contact information.

It is not uncommon for patients to travel outside of their current states to meet with top oncologists and thoracic surgeons across the country. These mesothelioma experts usually have a particular focus within their practice.

Mesothelioma Clinical Trials in Connecticut

The following clinical trials are in progress or actively recruiting participants in the state of Connecticut:

• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  Conditions:	Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
  Last Updated:	July 8, 2019
  Status:	Recruiting
  Locations:	Derby, CT. Fairfield, CT. Guilford, CT. Hartford, CT. New Haven, CT. North Haven, CT. Stamford, CT. Trumbull, CT. Waterbury, CT. West Haven, CT.

• Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

  Conditions:	Unresectable Pleural or Peritoneal Malignant Mesothelioma
  Last Updated:	July 2, 2019
  Status:	Active, not recruiting
  Locations:	New Haven, CT. Scottsdale, AZ. La Jolla, CA. Los Angeles, CA. San Francisco, CA. Santa Monica, CA. Newark, DE. Tampa, FL. Augusta, GA. Chicago, IL.

• Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

  Conditions:	Mesothelioma
  Last Updated:	July 1, 2019
  Status:	Active, not recruiting
  Locations:	New Haven, CT. San Francisco, CA. Tampa, FL. Chicago, IL. Baltimore, MD. Detroit, MI. Grand Rapids, MI. Rochester, MN. New York, NY. Cleveland, OH.

• Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

  Conditions:	Mesothelioma
  Last Updated:	June 6, 2019
  Status:	Active, not recruiting
  Locations:	Norwich, CT. Calgary, Alberta. La Jolla, CA. Aurora, CO. Tampa, FL. Chicago, IL. New Orleans, LA. Bethesda, MD. Rochester, MN. Buffalo, NY.

• A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

  Conditions:	Advanced Solid Tumors Cancer
  Last Updated:	June 6, 2019
  Status:	Recruiting
  Locations:	New Haven, CT. La Jolla, CA. Sacramento, CA. Stanford, CA. Huntersville, NC. Greenville, SC. Dallas, TX. San Antonio, TX. Fairfax, VA.

Connecticut Cancer Support Services

While receiving treatment, mesothelioma patients may find a need for temporary lodging, patient transport, physical therapy or counseling. We have compiled a list of these cancer support services in Connecticut for your convenience.

Mesothelioma Treatment Alerts & Clinical Trials

Free & Delivered within 24 hours